Matricelf
Tel Aviv, Israel· Est.
Autologous iPSC‑based tissue implants for curative spinal cord injury and broader regenerative medicine.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Autologous iPSC‑based tissue implants for curative spinal cord injury and broader regenerative medicine.
Spinal Cord InjuryTraumatic Brain InjuryStrokeMyocardial Infarction
Technology Platform
Autologous 3‑D tissue engineering using patient‑derived extracellular matrix hydrogel and iPSCs to create personalized neural or cardiac implants with reduced immunogenicity.
Opportunities
Successful SCI trials could validate a platform for rapid expansion into stroke, TBI, and cardiac repair, creating a suite of personalized regenerative therapies.
Risk Factors
Regulatory approval, scalable GMP manufacturing of autologous implants, and high clinical trial costs pose significant execution risks.
Competitive Landscape
Few competitors offer fully autologous iPSC‑based tissue implants; Matricelf differentiates through its patient‑specific ECM hydrogel and modular 3‑D engineering approach.